AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Evaluating the Risk of Adverse Cardiovascular Events Among Older Adults with Diagnosed Peripheral Artery Disease in the US

By Muntner P, Watanabe AH, Bash LD et al.

Introduction: Atherosclerotic cardiovascular disease (ASCVD), including peripheral artery disease (PAD), is associated with major adverse cardiovascular events (MACE), major adverse limb events (MALE), and mortality. PAD often co-occurs with diabetes (DM), coronary artery disease (CAD), and chronic kidney disease (CKD), which may further amplify risk. Estimating the prevalence of diagnosed PAD and associated MACE, MALE, and mortality risk may inform strategies to identify the highest risk patients and optimize prevention. Research Question: To estimate the prevalence of diagnosed PAD among older US adults and the associated risk of MACE, MALE, and mortality, overall and in those with comorbid DM, CAD, and CKD. Methods: Fee-for-service Medicare beneficiaries were identified from CMS Chronic Conditions Data Warehouse Research Identifiable Files. Patients were stratified as diagnosed with PAD (PAD+) or not (PAD-) as of Jan 1, 2023, after which they were followed over 1 year for outcomes: MACE-plus (ischemic stroke, acute limb ischemia/major amputation, myocardial infarction, urgent arterial revascularization, cardiovascular death), MALE (acute/chronic limb ischemia, lower extremity arterial revascularization or amputation), and all-cause mortality. Cox proportional hazards models evaluated associations of PAD and its interactions with DM, CAD, and CKD on outcomes. Results: Among 8,833,456 patients, 7.5% (n=663,119) had diagnosed PAD. Adults with PAD were older (mean age: 78.1 vs. 75.2 years), more often male (49.0% vs. 42.3%), and had more ASCVD risk factors, including DM (61.0% vs. 14.1%), CAD (59.9% vs. 11.4%), and CKD (44.1% vs. 8.6%). Overall, 85.7% of the PAD+ cohort vs. 23.8% of the PAD- had DM, CAD, and/or CKD. PAD was associated with increased hazards of all outcomes, regardless of the presence and any combination of concurrent DM, CAD, or CKD (Table 1). This effect was stronger for MALE, where PAD more than doubled the risk among patients with all three risk amplifiers. However, in the absence of risk amplifiers, the relative risk increase associated with PAD was even higher (e.g., for MALE, HR: 7.19 [95%CI: 7.02, 7.36]). Among patients with PAD, the presence of DM, CAD, or CKD was associated with increased hazards of having an ASCVD event and mortality (Table 2). Conclusions: A substantial proportion of older adults in the US had diagnosed PAD, which was associated with increased risk of MACE-plus, MALE, and all-cause mortality compared to those without PAD. Comorbid DM, CAD, or CKD were common and shown to increase risks in any combination. These findings underscore the urgent need for strategies to identify patients with PAD, characterize additional risk, implement intensive preventive care, and manage patients as outlined in guidelines.

doi.org/10.1161/circ.154.suppl_1.5196Populations

AgingResearch.News